← Akzo Nobel NV overview

Akzo Nobel NV vs Celanese: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Akzo Nobel NV (AKZA.AS)

Q3 2026
▲4

AkzoNobel advances $25B Axalta merger, sells SE Asia unit, Q2 profit up

  • Q2 profit rises, full-year targets on track AkzoNobel's Q2 profit rose to €139 million from €124 million, with adjusted EBITDA up to €398 million. Revenue slipped slightly to €2.59 billion, but the company remains on track for full-year targets and expects €100 million EBITDA improvement. This supports the share price by showing steady profitability and progress.

    Earnings growth and target confirmation directly support the investment case and share price.

  • Axalta merger progresses with governance tweaks and strong Axalta results AkzoNobel and Axalta improved merger governance (annual director elections, lower approval threshold) after shareholder talks. Axalta posted record Q2 EBITDA of $305 million and projects $600 million in annual cost synergies. These developments keep the $25 billion merger on track, boosting confidence in future value.

    Merger progress and partner strength are key catalysts for the pending deal and future earnings.

  • AkzoNobel sells SE Asia decorative paints unit to Nippon Paint AkzoNobel agreed to sell its Southeast Asian architectural coatings business to Nippon Paint for $1.35 billion, concluding its strategic review of Asian decorative paints. This simplifies the business and raises cash ahead of the Axalta merger, likely supporting the share price.

    Divestment sharpens focus and strengthens balance sheet before merger, a positive for shareholders.

  • EU set to approve Axalta deal with vehicle-refinish divestments AkzoNobel will offer divestments in vehicle refinish to satisfy EU regulators, and the EC is expected to approve the $25 billion Axalta deal. The powder coating concerns were dropped. This removes a major regulatory hurdle, making the merger completion more likely and supporting the share price.

    Regulatory clearance is a critical step for the merger to close, directly affecting deal certainty and valuation.

August 2026
▲4

AkzoNobel advances $25B Axalta merger, sells SE Asia unit, Q2 profit up

  • Q2 profit rises, full-year targets on track AkzoNobel's Q2 profit rose to €139 million from €124 million, with adjusted EBITDA up to €398 million. Revenue slipped slightly to €2.59 billion, but the company remains on track for full-year targets and expects €100 million EBITDA improvement. This supports the share price by showing steady profitability and progress.

    Earnings growth and target confirmation directly support the investment case and share price.

  • Axalta merger progresses with governance tweaks and strong Axalta results AkzoNobel and Axalta improved merger governance (annual director elections, lower approval threshold) after shareholder talks. Axalta posted record Q2 EBITDA of $305 million and projects $600 million in annual cost synergies. These developments keep the $25 billion merger on track, boosting confidence in future value.

    Merger progress and partner strength are key catalysts for the pending deal and future earnings.

  • AkzoNobel sells SE Asia decorative paints unit to Nippon Paint AkzoNobel agreed to sell its Southeast Asian architectural coatings business to Nippon Paint for $1.35 billion, concluding its strategic review of Asian decorative paints. This simplifies the business and raises cash ahead of the Axalta merger, likely supporting the share price.

    Divestment sharpens focus and strengthens balance sheet before merger, a positive for shareholders.

  • EU set to approve Axalta deal with vehicle-refinish divestments AkzoNobel will offer divestments in vehicle refinish to satisfy EU regulators, and the EC is expected to approve the $25 billion Axalta deal. The powder coating concerns were dropped. This removes a major regulatory hurdle, making the merger completion more likely and supporting the share price.

    Regulatory clearance is a critical step for the merger to close, directly affecting deal certainty and valuation.

Latest
▲4

AkzoNobel advances $25B Axalta merger, sells SE Asia unit, Q2 profit up

  • Q2 profit rises, full-year targets on track AkzoNobel's Q2 profit rose to €139 million from €124 million, with adjusted EBITDA up to €398 million. Revenue slipped slightly to €2.59 billion, but the company remains on track for full-year targets and expects €100 million EBITDA improvement. This supports the share price by showing steady profitability and progress.

    Earnings growth and target confirmation directly support the investment case and share price.

  • Axalta merger progresses with governance tweaks and strong Axalta results AkzoNobel and Axalta improved merger governance (annual director elections, lower approval threshold) after shareholder talks. Axalta posted record Q2 EBITDA of $305 million and projects $600 million in annual cost synergies. These developments keep the $25 billion merger on track, boosting confidence in future value.

    Merger progress and partner strength are key catalysts for the pending deal and future earnings.

  • AkzoNobel sells SE Asia decorative paints unit to Nippon Paint AkzoNobel agreed to sell its Southeast Asian architectural coatings business to Nippon Paint for $1.35 billion, concluding its strategic review of Asian decorative paints. This simplifies the business and raises cash ahead of the Axalta merger, likely supporting the share price.

    Divestment sharpens focus and strengthens balance sheet before merger, a positive for shareholders.

  • EU set to approve Axalta deal with vehicle-refinish divestments AkzoNobel will offer divestments in vehicle refinish to satisfy EU regulators, and the EC is expected to approve the $25 billion Axalta deal. The powder coating concerns were dropped. This removes a major regulatory hurdle, making the merger completion more likely and supporting the share price.

    Regulatory clearance is a critical step for the merger to close, directly affecting deal certainty and valuation.

Celanese Corporation (CE)

Q3 2026
▲4

Celanese cuts debt, wins legal case, raises prices, adds robot demand

  • Debt reduction via Nutrinova stake sale Celanese is selling another 19% of its Nutrinova food-ingredients venture to Mitsui for about $152 million, cutting its stake to 11%. The cash goes toward paying down debt, part of a plan to raise $1 billion from asset sales by 2027. Lower debt makes the company safer and supports the stock.

    This is a major new step in Celanese's deleveraging plan, directly improving its financial health and reducing risk.

  • Legal claims dismissed in Amsterdam A Dutch court threw out all damages claims against Celanese from Shell and Repsol over past ethylene purchases. This removes a potential financial liability and simplifies the risk picture. With one less legal overhang, investors can focus on the business, which helps the stock.

    The court dismissal eliminates a significant legal risk that had been weighing on Celanese shares.

  • Price hikes on key acetyl products Celanese raised prices on four acetyl products, including acetic acid and vinyl acetate monomer, by up to $0.06 per pound in the US and Canada, with increases elsewhere. Higher prices can boost revenue and profit, especially after its Acetyl Chain sales jumped 28% in the second quarter. This supports the stock.

    The price increases show Celanese's ability to improve pricing, a direct positive for earnings and investor sentiment.

  • New demand from humanoid robot partnership Celanese teamed up with VIGOR Precision to supply high-performance plastics for humanoid robot joints, aiming to cut joint weight by over 30% versus metal. This opens a new market for Celanese's specialty materials, potentially adding future sales and showing growth beyond traditional chemicals.

    The partnership represents a new demand source and innovation, which could drive future revenue growth.

August 2026
▲4

Celanese cuts debt, wins legal case, raises prices, adds robot demand

  • Debt reduction via Nutrinova stake sale Celanese is selling another 19% of its Nutrinova food-ingredients venture to Mitsui for about $152 million, cutting its stake to 11%. The cash goes toward paying down debt, part of a plan to raise $1 billion from asset sales by 2027. Lower debt makes the company safer and supports the stock.

    This is a major new step in Celanese's deleveraging plan, directly improving its financial health and reducing risk.

  • Legal claims dismissed in Amsterdam A Dutch court threw out all damages claims against Celanese from Shell and Repsol over past ethylene purchases. This removes a potential financial liability and simplifies the risk picture. With one less legal overhang, investors can focus on the business, which helps the stock.

    The court dismissal eliminates a significant legal risk that had been weighing on Celanese shares.

  • Price hikes on key acetyl products Celanese raised prices on four acetyl products, including acetic acid and vinyl acetate monomer, by up to $0.06 per pound in the US and Canada, with increases elsewhere. Higher prices can boost revenue and profit, especially after its Acetyl Chain sales jumped 28% in the second quarter. This supports the stock.

    The price increases show Celanese's ability to improve pricing, a direct positive for earnings and investor sentiment.

  • New demand from humanoid robot partnership Celanese teamed up with VIGOR Precision to supply high-performance plastics for humanoid robot joints, aiming to cut joint weight by over 30% versus metal. This opens a new market for Celanese's specialty materials, potentially adding future sales and showing growth beyond traditional chemicals.

    The partnership represents a new demand source and innovation, which could drive future revenue growth.

Latest
▲4

Celanese cuts debt, wins legal case, raises prices, adds robot demand

  • Debt reduction via Nutrinova stake sale Celanese is selling another 19% of its Nutrinova food-ingredients venture to Mitsui for about $152 million, cutting its stake to 11%. The cash goes toward paying down debt, part of a plan to raise $1 billion from asset sales by 2027. Lower debt makes the company safer and supports the stock.

    This is a major new step in Celanese's deleveraging plan, directly improving its financial health and reducing risk.

  • Legal claims dismissed in Amsterdam A Dutch court threw out all damages claims against Celanese from Shell and Repsol over past ethylene purchases. This removes a potential financial liability and simplifies the risk picture. With one less legal overhang, investors can focus on the business, which helps the stock.

    The court dismissal eliminates a significant legal risk that had been weighing on Celanese shares.

  • Price hikes on key acetyl products Celanese raised prices on four acetyl products, including acetic acid and vinyl acetate monomer, by up to $0.06 per pound in the US and Canada, with increases elsewhere. Higher prices can boost revenue and profit, especially after its Acetyl Chain sales jumped 28% in the second quarter. This supports the stock.

    The price increases show Celanese's ability to improve pricing, a direct positive for earnings and investor sentiment.

  • New demand from humanoid robot partnership Celanese teamed up with VIGOR Precision to supply high-performance plastics for humanoid robot joints, aiming to cut joint weight by over 30% versus metal. This opens a new market for Celanese's specialty materials, potentially adding future sales and showing growth beyond traditional chemicals.

    The partnership represents a new demand source and innovation, which could drive future revenue growth.